A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection

PHASE3CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 2, 2022

Primary Completion Date

February 8, 2024

Study Completion Date

February 8, 2024

Conditions
Melanoma
Interventions
BIOLOGICAL

Nivolumab/rHuPH20

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

Trial Locations (16)

2450

Local Institution - 0038, Coffs Harbour

2500

Local Institution - 0003, Wollongong

3550

Local Institution - 0008, Bendigo

9000

Local Institution - 0029, Ghent

20141

Local Institution - 0016, Milan

28036

Local Institution - 0002, Madrid

28050

Local Institution - 0043, Madrid

37920

Local Institution - 0044, Knoxville

41009

Local Institution - 0005, Seville

46014

Local Institution - 0030, Valencia

46804

Local Institution - 0004, Fort Wayne

80131

Local Institution - 0015, Napoli

45-061

Local Institution - 0034, Opole

85-796

Local Institution - 0036, Bydgoszcz

08003

Local Institution - 0026, Barcelona

LE1 5WW

Local Institution - 0040, Leicester

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY